查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591969

特发性肺纤维化市场：按药物类型、分销管道和最终用户划分 - 全球预测 2025-2030

Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone), Distribution Channel (Offline, Online), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年特发性肺纤维化市场价值为34.6亿美元，预计2024年将达到36.5亿美元，复合年增长率为5.47%，到2030年将达到50.3亿美元。

特发性肺纤维化（IPF）是进行性慢性肺部疾病，其特征是肺组织出现不明原因的疤痕，导致严重的呼吸道疾病。就市场研究范围而言，特发性肺纤维化（IPF）的主要定义是其在世界老龄化人口中日益流行，增加了对有效治疗方案和患者管理解决方案的需求。由于缺乏明确的治疗方法，强调了解决 IPF 的必要性，因此必须专注于药物开发和治疗方法强化。最终用户主要是专注于创新药物发现、先进诊断工具和综合护理策略的製药公司、医疗保健提供者和研究机构。影响 IPF 市场的主要成长要素包括基因组和生物技术的进步、政府透过资金和优惠政策提供的支持，以及倡导早期诊断和治疗的提高认识活动。最新的潜在商机在于个人化医疗和生技药品，它们有望透过解决个体的遗传和分子特征来彻底改变 IPF 治疗。鼓励企业投资尖端合作研究，利用人工智慧加速药物发现和开发。儘管有这些机会，挑战仍然存在，包括高昂的治疗成本、严格的监管要求以及 IPF 的复杂性使配方变得复杂。此外，对病理学的有限了解也是一个主要障碍。市场相关人员应致力于透过专注于基因编辑技术、液态切片等改进的诊断方法以及以患者为中心的护理模式等创新领域来发展业务。对市场性质的讨论表明，持续的研发和策略联盟正在推动竞争格局的发展，以加强产品平臺。强调全人治疗解决方案和促进全面的患者支援服务是有效引导市场并确保竞争优势和患者福祉的关键策略。

主要市场统计
基准年[2023] 34.6亿美元
预测年份 [2024] 36.5亿美元
预测年份 [2030] 50.3亿美元
复合年增长率（%） 5.47%

市场动态：快速发展的特发性肺纤维化市场的关键市场洞察

特发性肺纤维化市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 特发性肺纤维化盛行率增加
    • 医疗和诊断技术的进步
  • 市场限制因素
    • 治疗/治疗费用高
  • 市场机会
    • 精准医疗创新与标靶治疗开发
    • 特发性肺纤维化的罕见疾病认定和 IPF 治疗药物开发的奖励
  • 市场挑战
    • 关于 IPF 治疗的副作用和潜在风险的治疗问题

波特五力：驾驭特发性纤维化市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解特发性肺纤维化市场的外部影响

外部宏观环境因素在塑造特发性肺纤维化市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解特发性肺纤维化市场的竞争格局

对特发性肺纤维化市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵特特发性肺纤维化市场供应商的绩效评估

FPNV 定位矩阵是评估特发性肺纤维化市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製特发性肺纤维化市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对特发性肺纤维化市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 特发性肺纤维化盛行率增加
      • 医疗和诊断技术的进步
    • 抑制因素
      • 治疗费用上涨
    • 机会
      • 精准医学创新与标靶治疗的发展
      • 特发性肺纤维化的罕见疾病认定和 IPF 治疗药物开发的奖励
    • 任务
      • 对 IPF 治疗副作用和潜在风险的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章特发性肺纤维化市场药物按类型

  • 尼达尼布
  • Pirfenidone

第七章特发性肺纤维化市场：按通路

  • 离线
  • 在线的

第 8 章特发性肺纤维化市场：依最终用户分类

  • 门诊手术中心
  • 居家护理设施
  • 医院/诊所

第九章美洲特发性肺纤维化市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区特发性肺纤维化市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲特发性肺纤维化市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Algernon Pharmaceuticals Inc.
  • Alkem Laboratories Ltd.
  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Camber Pharmaceuticals, Inc. by Hetero Labs Limited
  • Chemo Healthcare Pvt. Ltd.
  • Cipla Limited
  • Dr Reddy's Laboratories Ltd.
  • FibroGen, Inc.
  • Galapagos NV
  • Glenmark Pharmaceuticals Ltd.
  • GNI Group Ltd.
  • Horizon Therapeutics PLC by Amgen Inc.
  • Lupin Ltd.
  • MediciNova, Inc.
  • Merck & Co.
  • Mission Therapeutics
  • MSN Laboratories Private Limited
  • Sandoz International GmbH
  • Sanify Healthcare Private Limited
  • Shionogi & Co., Ltd.
  • Teva Pharmaceuticals, Inc.
Product Code: MRR-2A0283E25610

The Idiopathic Pulmonary Fibrosis Market was valued at USD 3.46 billion in 2023, expected to reach USD 3.65 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 5.03 billion by 2030.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and chronic lung condition characterized by unexplained scarring of lung tissue, leading to severe respiratory issues. In the scope of market research, IPF is defined primarily by its growing incidence rate among the global aging population, thus prompting an increased necessity for effective treatment options and patient management solutions. The necessity for addressing IPF is underscored by the lack of definitive curative therapies, making it imperative to focus on drug development and therapy enhancement. Application and end-use scope principally encompass pharmaceutical companies, healthcare providers, and research institutions focusing on innovative drug discovery, advanced diagnostic tools, and comprehensive care strategies. Key growth factors influencing the IPF market include advancements in genomics and biotechnology, governmental support through funding and favorable policies, and increasing awareness initiatives advocating for early diagnosis and treatment. The latest potential opportunities lie in personalized medicine and biologics, which promise to revolutionize IPF treatment by catering to individual genetic and molecular profiles. Companies are recommended to invest in cutting-edge research collaborations and leverage artificial intelligence for accelerated drug discovery and development. Despite these opportunities, challenges persist such as high treatment costs, stringent regulatory requirements, and the complex nature of IPF which complicates drug formulation. Moreover, the limited understanding of the disease pathogenesis poses significant hurdles. Market players should focus on areas of innovation such as gene editing technologies, improved diagnostic methodologies like liquid biopsy, and patient-centric care models for business growth. Insights into the market's nature suggest a competitive landscape, driven by continuous R&D and strategic partnerships to enhance product pipelines. Emphasizing holistic treatment solutions and fostering comprehensive patient support services will be crucial strategies to navigate the market effectively, ensuring both competitive advantage and patient welfare.

KEY MARKET STATISTICS
Base Year [2023] USD 3.46 billion
Estimated Year [2024] USD 3.65 billion
Forecast Year [2030] USD 5.03 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Idiopathic Pulmonary Fibrosis Market

The Idiopathic Pulmonary Fibrosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of idiopathic pulmonary fibrosis
    • Advancements in the medical and diagnostic technology
  • Market Restraints
    • High cost of therapies and treatments
  • Market Opportunities
    • Innovations in the precision medicine and development of targeted therapies
    • Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
  • Market Challenges
    • Concerns associated with side-effects and potential risk of IPF treatment

Porter's Five Forces: A Strategic Tool for Navigating the Idiopathic Pulmonary Fibrosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Idiopathic Pulmonary Fibrosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Idiopathic Pulmonary Fibrosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Idiopathic Pulmonary Fibrosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Idiopathic Pulmonary Fibrosis Market

A detailed market share analysis in the Idiopathic Pulmonary Fibrosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Idiopathic Pulmonary Fibrosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Idiopathic Pulmonary Fibrosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Idiopathic Pulmonary Fibrosis Market

A strategic analysis of the Idiopathic Pulmonary Fibrosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Idiopathic Pulmonary Fibrosis Market, highlighting leading vendors and their innovative profiles. These include Algernon Pharmaceuticals Inc., Alkem Laboratories Ltd., AstraZeneca PLC, Avalyn Pharma Inc., Biogen, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Camber Pharmaceuticals, Inc. by Hetero Labs Limited, Chemo Healthcare Pvt. Ltd., Cipla Limited, Dr Reddy's Laboratories Ltd., FibroGen, Inc., Galapagos NV, Glenmark Pharmaceuticals Ltd., GNI Group Ltd., Horizon Therapeutics PLC by Amgen Inc., Lupin Ltd., MediciNova, Inc., Merck & Co., Mission Therapeutics, MSN Laboratories Private Limited, Sandoz International GmbH, Sanify Healthcare Private Limited, Shionogi & Co., Ltd., and Teva Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Idiopathic Pulmonary Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Nintedanib and Pirfenidone.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Home Care Facilities, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of idiopathic pulmonary fibrosis
      • 5.1.1.2. Advancements in the medical and diagnostic technology
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapies and treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in the precision medicine and development of targeted therapies
      • 5.1.3.2. Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with side-effects and potential risk of IPF treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Idiopathic Pulmonary Fibrosis Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Nintedanib
  • 6.3. Pirfenidone

7. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Offline
  • 7.3. Online

8. Idiopathic Pulmonary Fibrosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Home Care Facilities
  • 8.4. Hospitals & Clinics

9. Americas Idiopathic Pulmonary Fibrosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Idiopathic Pulmonary Fibrosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Algernon Pharmaceuticals Inc.
  • 2. Alkem Laboratories Ltd.
  • 3. AstraZeneca PLC
  • 4. Avalyn Pharma Inc.
  • 5. Biogen, Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol Myers Squibb
  • 8. Camber Pharmaceuticals, Inc. by Hetero Labs Limited
  • 9. Chemo Healthcare Pvt. Ltd.
  • 10. Cipla Limited
  • 11. Dr Reddy's Laboratories Ltd.
  • 12. FibroGen, Inc.
  • 13. Galapagos NV
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. GNI Group Ltd.
  • 16. Horizon Therapeutics PLC by Amgen Inc.
  • 17. Lupin Ltd.
  • 18. MediciNova, Inc.
  • 19. Merck & Co.
  • 20. Mission Therapeutics
  • 21. MSN Laboratories Private Limited
  • 22. Sandoz International GmbH
  • 23. Sanify Healthcare Private Limited
  • 24. Shionogi & Co., Ltd.
  • 25. Teva Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023